Exelixis | EXEL - Operating Profit

Stock Price
50.13
Daily Change
-0.97 -1.90%
Monthly
12.96%
Yearly
10.42%
Q2 Forecast
49.12

Exelixis reported $251.34M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Exelixis USD 251.34M 15.43M Mar/2026
Genmab DKK 260M 199M Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
MacroGenics USD -12.1M 30.74M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sanofi EUR 1.5B 2.29B Dec/2025
Takeda JPY -13.62B 182.44B Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026